Intranasal treatment for mild traumatic brain injury (broad agency announcement number SO190192)
Active Definitive Contract Awarded Last action
- Contract number
- HT942523C0036
- Awardee
-
Beyond Barriers Therapeutics, Inc. UEI FF4KBK5KEXL9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,878,956
Award facts
- Opportunity
-
- BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical Research and Development Special Notice · W81XWH18SSOC1 · Posted Aug 1, 2018
- Contract value 100% obligated
- $1,878,955.92 Current and potential, with all options
- Completion date 94% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Air Mobility Command Air Force, Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Basic Research
- Pricing
- Fixed Price Level of Effort
- Place of performance
- Glencoe, IL 60022, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $0 | |
| Funding Only Action | $878,956 | |
| Original award | $1,000,000 |
About this award
Air Mobility Command awarded a $1.88 million fixed-price level-of-effort definitive contract to Beyond Barriers Therapeutics, Inc. on July 25, 2023, for an intranasal treatment for mild traumatic brain injury. No set-aside was used. Work is performed in Glencoe, Illinois, and the contract carries an ultimate completion date of January 24, 2027. The $1.88 million figure is the ceiling value.
The originating opportunity is Broad Agency Announcement SO190192, a Special Notice issued by the Department of the Army Medical Command under 10 U.S.C. 2358 to solicit extramural research and development proposals. The BAA covers intranasal treatment for mild traumatic brain injury, with research areas meant to inform both military and civilian medical practice. It ran from August 1, 2018 through July 31, 2023, accepted pre-proposals on a rolling basis through the electronic Biomedical Research Application Portal, and was open to non-Federal entities. Evaluation criteria were scientific and technical merit, feasibility, and potential contribution.
Quick answers
Who was awarded contract HT942523C0036?
HT942523C0036 was awarded to Beyond Barriers Therapeutics, Inc. by Defense Health Agency (Department of Defense) on July 25, 2023.
How much is contract HT942523C0036 worth?
The government has obligated $1,878,956 on HT942523C0036.
Which agency awarded contract HT942523C0036?
Defense Health Agency (Department of Defense) awarded HT942523C0036, with funding from Air Mobility Command (Air Force).
Was contract HT942523C0036 competed?
The extent of competition for HT942523C0036 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award